Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$0.00$0.00no prior Q2 2019 on file Net Income-$5.34M-$5.34MN/M vs Q2 2019 EPS Diluted-$0.13-$0.13N/M vs Q2 2019 Operating Income-$5,351,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end